With a backdrop of mounting industry disruption and transition, Pharm Exec’s latest listing of the top global biopharma sales ...

Approval was based on results from the Phase III inMIND trial, which demonstrated a statistically significant and clinically ...

The decision to advance prasinezumab to Phase III was based on results from the Phase IIb PADOVA trial, which demonstrated ...

FDA approves first targeted therapy for bullous pemphigoid (BP): Dupixent (dupilumab) becomes the first and only targeted ...

The traditional approach to trial management relies on a mix of solutions that often become siloed and difficult to integrate ...

Approval of first twice-yearly HIV pre-exposure prophylaxis was based on results from the Phase III PURPOSE 1 and PURPOSE 2 ...

Harliku becomes the first FDA-approved treatment for alkaptonuria, indicated to reduce homogentisic acid levels in affected ...

The investigational MRI contrast agent, gadoquatrane, is designed to deliver effective imaging at a significantly reduced ...

The companies are working together to make it easier for companies to offer health plans that include these medications.

Results from the Phase III TEMPLE trial show that patients administered Qulipta (atogepant) experienced significantly fewer ...

For more than three decades, U.S. pharmacy policy has operated under a consistent—if complex—structure: Well-intended ...

With acquisition of Verve Therapeutics, Eli Lilly aims to advance next-generation cardiovascular care through one-time gene ...